At Pulmatrix, we are committed to communicating clear and consistent information. Here we feature current and historic content concerning our science, our pipeline, and our corporate initiatives and achievements. Please check in often for the most recent press releases and information.
Dec 8, 2015
Pulmatrix, Inc. (NASDAQ: PULM), a biopharmaceutical company developing inhaled therapies for pulmonary disease, today announced the appointment of Mark Iwicki as chairman of its board of...
Nov 12, 2015
Pulmatrix, Inc. (NASDAQ: PULM) reports third quarter financial results and provides an update on the progress year to date on the business and its drug development pipeline. Since the beginning of...
Oct 9, 2015
Pulmatrix, Inc., (NASDAQ: PULM) will be webcasting the Company's investor presentation at two upcoming investor conferences. Pulmatrix will be presenting at the Dawson James 2015 Small Cap Growth...
Oct 8, 2015
Data to be Presented at 2015 North American Cystic Fibrosis Conference
Pulmatrix, Inc. (NASDAQ: PULM) today announced preclinical data showing that PUR1900 (iSPERSE™-formulated itraconazole), which is being developed as the first inhaled antifungal medication for...
Oct 1, 2015
Celdara Medical, LLC and Pulmatrix, Inc. (NASDAQ: PULM) today announced that the National Heart Lung and Blood Institute of the National Institutes of Health has awarded a three-year, $1.7 million...